CEBPA and acute myeloid leukemia: CSF3R mutations define a distinct high‐risk subset of AML, characterized by reduced remission rates, lower measurable residual disease negativity, and significantly inferior survival—most notably among patients harboring CEBPA basic leucine zipper domain mutations.